Literature DB >> 19284787

Alpha(E)C, the C-terminal extension of fibrinogen, has chaperone-like activity.

Huadong Tang1, Yan Fu, Shunli Zhan, Yongzhang Luo.   

Abstract

Human fibrinogen is an important coagulation factor as well as an acute phase protein in the circulatory system. Fibrinogen-420 is distinguished from the conventional alpha chain of fibrinogen-340 by the presence of an additional 236-residue carboxyl terminus globular domain (alpha(E)C). The alpha(E)C domain of human fibrinogen-420 is a stable and early proteolytic cleavage product in the circulation. A genuine physiological function for alpha(E)C has not yet been established. Our study aims to characterize the novel chaperone-like activity of alpha(E)C. alpha(E)C efficiently protects a series of model proteins from thermally induced aggregation. Furthermore, alpha(E)C specifically recognizes the partially denatured form instead of the native form of citrate synthase (CS) and potentially protects it from thermally induced inactivation. The protective effect may result from formation of soluble complexes between alpha(E)C and partially denatured CS as tested by size exclusion column and electron microscope. In addition, alpha(E)C can keep the partially denatured luciferase in a folding competent state and help it refold in cooperation with rabbit reticulocyte lysate (RRL). Furthermore, alpha(E)C can also form complexes with thermally stressed plasma proteins. Our findings reveal the novel function of alpha(E)C as a chaperone-like protein, which not only provides new insights into the extracellular chaperone system but also has implications on the physiological and pathological relevance of fibrinogen.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19284787     DOI: 10.1021/bi900015n

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  4 in total

1.  Susceptibility to chronic thromboembolic pulmonary hypertension may be conferred by miR-759 via its targeted interaction with polymorphic fibrinogen alpha gene.

Authors:  Zhiyong Chen; Toshiaki Nakajima; Nobuhiro Tanabe; Kunihiko Hinohara; Seiichiro Sakao; Yasunori Kasahara; Koichiro Tatsumi; Yoshinori Inoue; Akinori Kimura
Journal:  Hum Genet       Date:  2010-07-31       Impact factor: 4.132

2.  Multistep growth of amyloid intermediates and its inhibition toward exploring therapeutic way: A case study using insulin B chain and fibrinogen.

Authors:  Naoki Yamamoto; Eri Chatani
Journal:  Biophys Physicobiol       Date:  2022-05-10

3.  Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease.

Authors:  Gonçalo da Costa; Cristina Ribeiro-Silva; Raquel Ribeiro; Samuel Gilberto; Ricardo A Gomes; António Ferreira; Élia Mateus; Eduardo Barroso; Ana V Coelho; Ana Ponces Freire; Carlos Cordeiro
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

Review 4.  Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective.

Authors:  Fanny Risser; Ivan Urosev; Joanan López-Morales; Yang Sun; Michael A Nash
Journal:  Biophys Rev       Date:  2022-04-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.